Vaccine
Conditions
Brief summary
Invasive meningococcal disease and meningococcal meningitis caused by Neisseria meningitidis have their highest incidence in children, with a second peak in adolescents and young adults. The most important disease-causing serogroups are meningococcal serogroups A (MenA) and MenC in Asia, such as China. The specific vaccine use in each country depends on the predominant serogroups, cost, and availability. conjugate vaccines are preferred to polysaccharide vaccines due to their impact on decreasing nasopharyngeal carriage of N. meningitidis and their overall increased immunogenicity in children. This clinical trial is planning to evaluate the immunogenicity and safety of bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine in Chinese healthy children aged 3 months to 5 years.
Detailed description
Invasive meningococcal disease and meningococcal meningitis caused by Neisseria meningitidis have their highest incidence in children, with a second peak in adolescents and young adults. The most important disease-causing serogroups are meningococcal serogroups A (MenA), MenB, MenC, MenW and MenY. Their prevalence varies geographically, MenA and MenC being more prominent in Asia. Neisseria meningitidis is one of the leading causes of bacterial meningitis globally. The annual number of cases related to invasive meningococcal disease (IMD) is estimated to be at least 1.2 million with 135 000 deaths.1 To combat IMD, an increasing number of countries have included vaccines against N. meningitidis in their routine immunization programs. The specific vaccine use in each country depends on the predominant serogroups, cost, and availability. Polysaccharide vaccines were used in high risk people in Saudi Arabia and Syria and in routine immunization in China and Egypt. In general, conjugate vaccines are preferred to polysaccharide vaccines due to their impact on decreasing nasopharyngeal carriage of N. meningitidis and their overall increased immunogenicity in children. This clinical trial is planning to evaluate the immunogenicity and safety of bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine in Chinese healthy children aged 3 months to 5 years.
Interventions
BIOLOGICALexperimental vaccine
bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(OLYMVAX Biological Co., LTD)
BIOLOGICALPositive control vaccine 1
bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(WALVAX Biological Co., LTD)
BIOLOGICALPositive control vaccine 2
bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(Royal (Wuxi) Biological Co., LTD)
Sponsors
Jiangsu Province Centers for Disease Control and Prevention
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
3 Months to 5 Years
Healthy volunteers
Yes
Inclusion criteria
* 3-5 months old group * Healthy infants aged 3-5months old as established by medical history and clinical examination * Subjects who was never administered meningococcal vaccine. * The subjects' guardians are able to understand and sign the informed consent * Subjects who can and will comply with the requirements of the protocol * Subjects with temperature ≤37.0°C on axillary setting 6-23 months old group * Healthy infants aged 6-23 months old as established by medical history and clinical examination * Subjects who was never administered meningococcal conjugate vaccine, or administered meningococcal polysaccharide vaccine over 3 months. * The subjects' guardians are able to understand and sign the informed consent * Subjects who can and will comply with the requirements of the protocol * Subjects with temperature ≤37.0°C on axillary setting 2-5 years old group * Healthy infants aged 2-5 years as established by medical history and clinical examination * Subjects who was never administered meningococcal conjugate vaccine, or administered meningococcal polysaccharide vaccine over 12 months. * The subjects' guardians are able to understand and sign the informed consent * Subjects who can and will comply with the requirements of the protocol * Subjects with temperature ≤37.0°C on axillary setting
Exclusion criteria
* Subjects who has a medical history of invasive meningococcal disease and meningococcal meningitis. * Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine * Severe malnutrition or dysgenopathy * Family history of seizures or progressive neurological disease * Family history of congenital or hereditary immunodeficiency * Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with injections or blood draws * Any acute infections in last 3 days * Any prior administration of immunodepressant or corticosteroids in last 14 days * Any prior administration of attenuated live vaccine in last 14 days * Any prior administration of subunit or inactivated vaccines in last 7 days * Had fever before vaccination, Subjects with temperature \>37.0°C on axillary setting * Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| seroconversion rates of antibodies after vaccination | 28 days after vaccination | seroconversion rates of antibodies against meningococcal serogroups A and C |
| Proportion of subjects reporting solicited injection-site reactions, solicited systemic reactions | Day 7 post-each dose | Proportion of subjects reporting solicited injection-site reactions, solicited systemic reactions within 7 days post-each dose |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of rSBA titers ≥1:128 and ≥1:8, and GMT for meningococcal serogroups A and C after vaccination in children aged 6-11 months. | 28 days after vaccination | Percentage of rSBA titers ≥1:128 and ≥1:8, and GMT for meningococcal serogroups A and C after vaccination in children aged 6-11 months. |
| Percentage of rSBA titers ≥1:128 and ≥1:8, and GMT for meningococcal serogroups A and C after vaccination in children aged 3-5 months. | 28 days after vaccination | Percentage of rSBA titers ≥1:128 and ≥1:8, and GMT for meningococcal serogroups A and C after vaccination in children aged 3-5 months. |
| Percentage of rSBA titers ≥1:128 and ≥1:8, and GMT for meningococcal serogroups A and C after vaccination in children aged 2-5 years. | 28 days after vaccination | Percentage of rSBA titers ≥1:128 and ≥1:8, and GMT for meningococcal serogroups A and C at day 28 post vaccination in children aged 2-5 years. |
| Proportion of subjects with Serious Adverse Events occurring throughout the trial | 28 days after vaccination | Proportion of subjects with Serious Adverse Events occurring throughout the trial |
| Proportion of subjects reporting unsolicited adverse events | 28 days after vaccination | Proportion of subjects reporting unsolicited adverse events |
| Percentage of rSBA titers ≥1:128 and ≥1:8, and GMT for meningococcal serogroups A and C after vaccination in children aged 12-23 months. | 28 days after vaccination | Percentage of rSBA titers ≥1:128 and ≥1:8, and GMT for meningococcal serogroups A and C after vaccination in children aged 12-23 months with two vaccination schedules. |
Outcome results
None listed